Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BSI-045B in moderate to severe atopic dermatitis
NCT05932654Phase 2Completed
- Sponsor
- Biosion
- Start
- Jul 2023
- Primary completion
- Sep 2024
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosakitug in atopic dermatitis (AD), sponsored by Biosion. Primary endpoints: Proportion of Patients Achieving at Least 75% Reduction in Eczema Area and Severity Index at 26 weeks and Safety Profile of Study Treatment at 36 weeks. Started Jul 2023; status: completed.
02
Drugs
bosakitug
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05932654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932654.